Comparison of local spectral modulation, and temporal correlation, of simultaneously recorded EEG/fMRI signals during ketamine and midazolam sedation.
Anna Forsyth, Rebecca McMillan, Doug Campbell, Gemma Malpas, Elizabeth Maxwell, Jamie Sleigh, Juergen Dukart, Joerg F Hipp, Suresh D Muthukumaraswamy
Psychopharmacology December 2018 DOI: 10.1007/s00213-018-5064-8 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Placebo-controlled, single-blind, three-way crossover study Peer reviewed |
|---|---|
| Interventions | Ketamine Midazolam Placebo |
| Topics | Ketamine Esketamine |
| Keywords | Electroencephalography Frequency analysis Midazolam Simultaneous EEG/FMRI |
| Key points | Simultaneous EEG/fMRI recording in a drug study proved feasible, with local spectral effects similar to prior non-simultaneous work. Ketamine produced widespread reduction of BOLD fALFF and varied EEG band effects, while midazolam increased fALFF in occipital, parietal, and temporal areas and frontal delta and beta power. EEG spectra were more sensitive to drug modulation than fALFF, with no clear spatial relationship between modalities. |
Abstract
The identification of biomarkers of drug action can be supported by non-invasive brain imaging techniques, such as electroencephalography (EEG) and functional magnetic resonance imaging (fMRI), with simultaneous collection plausibly overcoming the limitations of either modality alone. Despite this, few studies have assessed the feasibility and utility of recording simultaneous EEG/fMRI in a drug study. We used simultaneous EEG/fMRI to assess the modulation of neural activity by ketamine and midazolam, in a placebo-controlled, single-blind, three-way cross-over design. Specifically, we analysed the sensitivity and direction of the spectral effects of each modality and the temporal correlations between the modulations of power of the common EEG bands and the blood-oxygen-level-dependent (BOLD) signal. Demonstrating feasibility, local spectral effects were similar to those found in previous non-simultaneous EEG and fMRI studies. Ketamine administration resulted in a widespread reduction of BOLD fractional amplitude of low frequency fluctuations (fALFF) and a diverse pattern of effects in the different EEG bands. Midazolam increased fALFF in occipital, parietal, and temporal areas, and frontal delta and beta EEG power. While EEG spectra were more sensitive to pharmacological modulations than the fALFF bands, there was no clear spatial relationship between the two modalities. Additionally, ketamine modulated the temporal correlation strengths between the theta EEG band and the BOLD signal, whereas midazolam altered temporal correlations with the alpha and beta bands. Taken together, these results demonstrate the utility of simultaneous recording: each modality provides unique insights, and combinatorial analyses elicit more information than separate recordings.